Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01185 (vasopressin)
 23,126 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Four male divers were exposed to an environment of 26 and 31 atm abs He-O2 for 2 days. Urine was collected during the day (0700-1900 h) and at night (1900-0700 h) before (predive 1 atm abs air), during, and after (decompression and postdive 1 atm abs air) the exposure. Urine flow increased markedly and was mostly attributable to the urine flow during 1900-0700 h. The secretion of atrial natriuretic polypeptide (ANP) increased only at night during hyperbaria. On the other hand, the secretion of antidiuretic hormone (ADH) was suppressed, but increased during compression and the early phase of hyperbaric exposure before it decreased. Linear regression analysis showed that urinary excretion of ANP was correlated significantly with urine flow (r = 0.88, P less than 0.01) and that excretion of ADH negatively correlated with urine flow (r = -0.61, P less than 0.01). Urinary excretion of Na, Cl, Ca, and Mg increased significantly at night during hyperbaria, whereas there was no consistent change in the excretion of K and P. These results suggest that both stimulated ANP secretion and suppressed ADH secretion correlate with the increase of urine and that nocturia is mostly attributable to stimulated ANP secretion. We observed that urinary excretion of ANP increased significantly as early as during the compression phase, which suggested that ANP plays a decisive role in the early diuresis.
 ...
PMID:Urinary ANP, ADH, and electrolyte excretion during saturation-excursion diving to pressures equivalent to 250 and 300 m. 153 26

A double-blind study of nocturia due to benign prostatic hypertrophy is reported. The 21 patients received 0.2 ml of an antidiuretic hormone analogue, desamino-D-arginine vasopressin (Minirin) intranasally prior to evening bedtime. Though the frequency of nocturnal micturition fell in 13 patients, only 7 were considered to give a good clinical response. This drug can be tried in patients with benign prostatic hypertrophy if nocturia is distressing and the patient is unsuitable or disinclined for surgery.
 ...
PMID:Evaluation of a synthetic vasopressin analogue for treatment of nocturia in benign prostatic hypertrophy. A double-blind study. 616 1

Mnesic function has been tested in 5 patients suffering from central idiopathic diabetes insipidus 3 days after withdrawal of treatment (DDAVP) and 3 days after substitutive therapy. In general basal scores are low but no specific profile of disturbances has been found, except a general low score at the Benton test. Substitutive therapy induces a general improvement of the scores, mainly in the patients who did show the lower performances before treatment. Although our results are in agreement with positive action of vasopressin on mnesic function, we cannot ascertained that the observed effect is solely due to a central action of the hormone, since some metabolic consequences of the hormone administration (i.e. relapse of nycturia and consequently of sleep disturbances) could have indirect effects of cognitive function.
 ...
PMID:[Mnesic function in 5 patients suffering from central idiopathic diabetes insipidus (author's transl)]. 723 59

The purpose of this study is to determine the efficacy of desmopressin (DDAVP), a synthetic analogue of antidiuretic hormone, as an alternative therapy in the management of spinal cord injured (SCI) patients with neurogenic bladder dysfunction unresponsive to conventional therapy. Seven SCI patients (three men and four women) were treated with DDAVP after urodynamic evaluation. Despite treatment with anticholinergic agents, urodynamic evaluation demonstrated uninhibited detrusor contractions exceeding 30 cm H2O pressure at less than 300 ml cystometric capacity in all seven patients. Three patients had been managed with intermittent self-catheterization, but had socially unacceptable short intervals between catheterizations. Two women with incomplete injury were afflicted with significant nocturia (> 3 episodes/night). The remaining two patients managed with intermittent self-catheterization were troubled with nocturnal enuresis. The patients received 10 micrograms intranasal DDAVP once every 24 hours. Prior to DDAVP administration, the four patients who used DDAVP nightly experienced a median of four episodes of nocturia. After one month of DDAVP treatment, two patients had only one episode of nocturia per night and in the other two patients, nocturnal enuresis was completely eliminated. Three patients used daytime DDAVP administration at work to avoid frequent catheterization. The median period between bladder catheterizations increased from 2.5 hours before DDAVP to 6 hours while using DDAVP. Symptomatic improvement persisted during the follow-up period of 6-20 months (mean = 12). Side effects were infrequent; only one patient complained of transient headaches. Neither hyponatremia nor serum electrolyte abnormalities occurred. Our preliminary results suggest that DDAVP is safe and effective in the symptomatic management of complicated neurogenic bladder dysfunction in selected SCI patients.
 ...
PMID:DDAVP in the urological management of the difficult neurogenic bladder in spinal cord injury: preliminary report. 786 58

The mechanism of increased nocturnal urine production in adult patients complaining of nocturia has seldom been reported. The objective of this clinical study is to investigate the circadian rhythm of both urine production and plasma arginine-vasopressin (AVP) level, and the efficacy of intranasal instillation of 1-deamino-8-D-arginine-vasopressin (DDAVP) in adult patients complaining of nocturia. Eight patients (seven men, one woman) who ranged in age from 44 to 77 years (mean 64.1 years) were examined. Three of them suffered from Shy-Drager syndrome, and no patient had shown any improvement of symptoms in spite of administration of anti-cholinergic agents and restriction of water intake. Nocturnal urine volume was more than bladder capacity in all patients, and no patient showed normal elevation of nocturnal plasma AVP level. Intranasal administration of DDAVP of 5 or 10 micrograms revealed marked decrease in nocturia, and nocturnal urine volume (p < 0.01). There were mild side effects (headache, nasal obstruction, and hyponatremia) not requiring any treatment. In conclusion, DDAVP is a safe and effective treatment for adult patients complaining of nocturia due to hyperproduction of nocturnal urine and inappropriate nocturnal secretion of AVP.
 ...
PMID:[The effect of desmopressin (DDAVP) in patients complaining of nocturia]. 830 20

Diabetes insipidus is an uncommon condition characterized by polyuria and polydipsia. The symptoms and biochemical changes of this condition result from either a lack of antidiuretic hormone or renal insensitivity to its effect. Failure to produce or release antidiuretic hormone may result from cranial pathology, including trauma and surgery. The renal insensitivity to antidiuretic hormone that occurs in patients with nephrogenic diabetes insipidus may be caused by genetic factors, drugs (especially lithium) or specific disease processes. Patients may compensate for polyuria and nocturia by excessive water intake but show marked decreases in urine specific gravity and osmolality. Patients with severe and uncompensated symptoms develop marked dehydration, neurologic symptoms and encephalopathy. The water deprivation test is useful in diagnosing diabetes insipidus and in differentiating neurogenic from nephrogenic cases. Neurogenic diabetes insipidus may respond to nasal administration of desmopressin. Nephrogenic diabetes insipidus requires good hydration and monitoring of body chemistry. Thiazides and amiloride may relieve symptoms.
 ...
PMID:Evaluation and management of diabetes insipidus. 914 42

Aging often disturbs the normal circadian rhythm of urine production. The nocturia commonly seen with aging may result from the loss of nighttime vasopressin production or release that develops by childhood. Restoring the nocturnal increase in vasopressin can have a dramatic clinical response: improved quality of life and less risk of nighttime falls in carefully selected and accurately diagnosed patients.
 ...
PMID:Nocturnal polyuria in the elderly person. 933 61

Persistence of nocturia after prostatic resection in healthy patients without symptoms referred to residual bladder instability and to pathological polyuria seems to be caused by an increased urine production at night. The more accreditate mechanism involved is the relevant decreased ADH secretion pattern which occurs at night. In our study, patients with nocturnal poliuria showed significantly low plasmatic vasopressin levels compared with a control group. The aim of this study was to evaluate whether the persistence of nocturia after prostatic resection in healthy patients, without symptoms referred due to residual bladder instability and important polyuria, could be due to a decrease or a lack of increase in antidiuretic hormone (ADH) nocturnal levels following increased urine production at night. Serum ADH, atrial natriuretic peptide (ANP) and osmolality were assessed at 4-h intervals in 12 patients complaining of residual nocturia (group A) and in a control group of 13 patients who had undergone a complete resolution of nocturia after prostate ablation (group B). In the 25 patients involved in the study (mean age 65.8 years), no significant differences were observed in the two groups concerning mean age (67.5 years for group A, 64 years for group B). Mean nocturnal urine volume (1080 +/- 490 ml) in group A patients was significantly higher than in group B (500 +/- 100 ml) (p < 0.001), while no significant differences were found in diurnal diuresis. Mean plasma vasopressin levels of the 12 patients showing an increased nocturnal micturition were found to be significantly lower at all 4-h intervals when compared with the control group (p < 0.05). Individual fluctuations in serum osmolality were slight and insignificant within the normal range in all patients. The diurnal variation of plasma atrial natriuretic peptide was within the reference limits for all subjects during the 24-h period. Our results lead us to believe that residual nocturia after prostatic resection seems to be caused by an increased urine production at night due to a decreased ADH secretion pattern.
 ...
PMID:Circadian antidiuretic hormone variation in elderly men complaining of persistent nocturia after urinary flow obstruction removal. 982 93

Nocturia is a common and troublesome symptom in otherwise healthy elderly men and women. Nocturnal polyuria (an excessive nighttime urine output) has been documented to be a common finding in healthy men with lower urinary tract symptoms. It is also a presenting feature of various medical conditions, such as renal failure, hypercalcemia and diabetes. Fluid balance therapy is an option in those whose nocturia is secondary to nocturnal polyuria. If a reduction in fluid intake fails to reduce nocturnal frequency a variety of drug treatments may be beneficial. Several studies have confirmed the efficacy of intranasal DDAVP, a synthetic analog of antidiuretic hormone, in both healthy patients and those with neuropathic bladders, although fluid overload and hyponatremia are potential side effects. Other drug treatments include early evening diuretics, such as frusemide or bumetanide. More recently imipramine has shown therapeutic benefit in young adults with enuresis, and might prove to be useful in the elderly with nocturnal polyuria.
 ...
PMID:Fluid balance therapy of nocturia in women. 1020 67

Carbamazepine is chemically related to imipramine. It can reduce prostaglandin E2-like activity in inflammation. It caused overflow urinary incontinence, increased bladder capacity, sensitized renal tubules to antidiuretic hormone and leading to antidiuresis. This encouraged to use carbamazepine to treat primary enuresis. Twenty-six patients of either sex with a history of enuresis from birth were included in study. Their age ranged between 7 and 15 years (mean 9.3 years). They were assessed by history, physical examination, blood glucose, renal function tests, intravenous urogram and videocystourethrography. 30 days drug-free observation was performed to establish baseline voiding pattern. This was followed by two, 30 day treatment periods of either placebo or carbamazepine (200 mg) tablets, in a randomized, double-blind cross-over design. There was one week washout period between medications. The patients or their parents received calendar sheet to record wet and dry nights and offered subjective opinions concerning changes in sleep patterns, occurrence of nocturia and appearance of side-effects. A tablet was given to each patient before retiring. Those patients who showed no response to carbamazepine and placebo would be treated with 100 mg of indomethacin suppositories. The results show that of 26 patients 20 had 7 to 30 of 30 dry nights with carbamazepine, while 6 had 0 to 5 of 30 dry nights. The latter 6 patients reacted in the same manner with placebo, 4 of them showed better response with use of indomethacin. Six patients had 10 to 15 of 30 dry nights during placebo therapy and 20 had 0 to 6 of 30 dry nights. The mean number of dry nights was 3.92 +/- 5.22 with placebo and was 18.8 +/- 8.82 with carbamazepine. The difference in response to placebo and carbamazepine was statistically significant (p < 0.001). All the patients who responded sufficiently to indomethacin slept until the morning. No side effect was noticed with either treatment and repeated serum electrolytes and other laboratory tests were normal after treatment. It might be concluded that carbamazepine is useful for treatment of primary nocturnal enuresis.
 ...
PMID:Carbamazepine to treat primary nocturnal enuresis: double-blind study. 1065 88


1 2 3 4 Next >>